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The small ubiquitin-like modiﬁer (SUMO) is a short peptide that can be covalently linked to proteins
altering their function. SUMOylation is an essential post-translational modiﬁcation (PTM). Because of its
dynamic nature, low abundance levels, and technical limitations, the occupation of endogenous SU-
MOylated transcription factors at genomic loci is challenging to detect. The chromatin regulator Methyl
CpG binding protein 2 (MeCP2) is subjected to PTMs including SUMO. Mutations in MeCP2 lead to Rett
syndrome, a severe neurodevelopmental disorder. Here, we present an efﬁcient method to perform
sequential chromatin immunoprecipitation (Seq-ChIP) for detecting SUMOylated MeCP2 in neurons. This
Seq-ChIP technique is a useful tool to determine the occupancy of SUMOylated transcription and chro-
matin factors at speciﬁc genomic regions.
& 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The covalent addition of Small Ubiquitin Modiﬁer, SUMOyla-
tion, is an essential post-translational modiﬁcation (PTM) that
regulates diverse cellular processes including gene transcription,
chromatin remodeling, replication, chromosome segregation, and
DNA repair [1–4]. In mammals, the conjugation of SUMO to a ly-
sine residue in a target protein is mediated by three paralogs:
SUMO1–3 [1]. Most substrate proteins are rapidly deSUMOylated
by one of six Sentrin/SUMO-speciﬁc proteases (SENPs) [5]. Defects
in SUMOylation are associated with multiple diseases such as
cancer, heart failure, and neurodegeneration [6–8].
In the nervous system, SUMOylation plays a crucial function
with roles in synapse formation, axonal transport, and neuronal
excitability [9–12]. One way that neurons employ a rapid mod-
ulation of their transcription program in response to neuronal
activity is by regulating the PTMs of transcription factors. Tran-
scription factors can be modiﬁed by multiple PTMs, such as
phosphorylation, acetylation, ubiquitination, and SUMOylation
[13]. These PTMs modulate either the target factors binding ability
to DNA or interaction with protein co-factors [2].an open access article under the C
Donohoe).One neuronal factor that is regulated by PTMs is the Methyl
CpG binding protein 2(MeCP2) [8]. Although it was ﬁrst described
in the early 1990s as a transcriptional repressor binding methy-
lated DNA, it is now appreciated that MeCP2 can also function as
an activator and chromatin modiﬁer [8,14,15]. The importance of
MeCP2 is underscored as its mutations lead to a severe neurode-
velopmental disorder known as Rett syndrome (RTT) [16,8]. SU-
MOylation modiﬁes MeCP2, modulates its transcriptional activity,
and plays a crucial role in synaptic formation [17]. However, our
knowledge of the occupancy of endogenous SUMOylated MeCP2 at
speciﬁc neuronal regulatory regions is lacking. The identiﬁcation
of neuronal promoters harboring SUMOylated MeCP2 will deﬁne
its biological function during normal development. But detection
of endogenous SUMOylated chromatin and transcription factors at
genomic regions is problematic. Many SUMOylated proteins such
as MeCP2 and other chromatin and transcription factors are low in
abundance [18]. SUMOylation is very dynamic; therefore, identi-
ﬁcation of factors occupying speciﬁc genomic regions is difﬁcult
[18,19]. Furthermore, no antibodies exist that speciﬁcally re-
cognize a SUMOylated protein at particular genomic sites. Here,
we describe an efﬁcient sequential chromatin immunoprecipita-
tion (Seq-ChIP) method to identify SUMOylated MeCP2 at a given
neuronal genomic region in vivo.C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2.1. Neuronal cell culture
Mouse hippocampal neuronal cells (HT22) were maintained in
DMEM (Life Technologies) supplemented with 10% fetal calf ser-
um, 2 mM L-Glutamine, and 1 Penicillin/Streptomycin.
2.2. Chromatin immunoprecipitation (ChIP) antibodies and primer
selection
ChIP-grade antibodies were used for the Seq-ChIP. If an anti-
body has not been tested for ChIP, the efﬁciency of the antibody
can be tested by co-immunoprecipitation of the target protein as
previously described [20]. Western blotting can be performed
following the immunoprecipitation of the protein-DNA complexes
to check whether the SUMO PTM is enriched within the im-
munoprecipitated complex. This co-immunoprecipitation test
should be utilized to test other SUMOylated transcription factors
or chromatin modulators prior to the sequential ChIP. To design
primers for quantitative PCR, we selected an amplicons with a size
range of 75–200 base pair (bp) ﬂanking the regulatory regions in
genes of interest. We designed several sets of PCR primers located
upstream and downstream of each target genomic site and com-
pared the ChIP signals from these primer sets to observe protein
enrichment at a particular locus. PCR primers were designed with
the aid of several complimentary software applications such as
OLIGO Primer Analysis Software (http://www.oligo.net/), Primer 3
(www.bioinfo.ut.ee/primer3/), or Primer Premier (http://www.
premierbiosoft.com/primerdesign/). Prior to oligo synthesis, we
checked the speciﬁcity of the primers using the National Center for
Biotechnology (NCBI) Basic Local Alignment Search Tool (BLAST).
In addition, we obtained a melt curve analysis following the real-
time PCR analysis, to determine the speciﬁcity of the PCR primers.
A suitable set of PCR primers exhibits a single peak in the melt
curve. An agarose gel analysis of the PCR reaction product can be
also used to test the adequacy of the primers with the demon-
stration of a single band.
2.3. Sequential ChIP and quantitative Polymerase chain reaction
(PCR)
To detect SUMOylated MeCP2 at neuronal chromatin, we es-
tablished a Sequential-Chromatin immunoprecipitation (Seq-ChIP)
method:
(1) 2.5108 HT22 cells were crosslinked with 1% formaldehyde
for 10 min at room temperature with gentle agitation then
quenched by 125 mM glycine with agitation for an additional
10 min. The crosslinked cells were washed twice each with ice
cold phosphate buffered saline (PBS). The cells were pelleted
by centrifugation (Eppendorf 5424 centrifuge) for 5 min at
2000 rpm and resuspended in Lysis Buffer (1% SDS, 5 mM
EDTA, 50 mM Tris–HCl (pH 8.0), 150 mM NaCl) supplemented
with protease inhibitors (phenylmethanesulfonyl ﬂuoride
(PMSF) and protease inhibitor cocktail (Roche Diagnostics)
prior to use. The chromatin fraction was sheared using a mi-
crotip sonicator (Branson) on an output 7 setting for 22 cycles
of 10 s sonication followed by rest on ice for 50 s. A small
aliquot of the chromatin was removed and checked for soni-
cation efﬁciency (o500 bp) by agarose gel electrophoresis.
The sheared chromatin was then centrifuged for 10 min at 4 °C
maximum speed. The supernatant containing the chromatin
was diluted 1:10 with ChIP Dilution Buffer (20 mM Tris (pH
8.0), 1% Triton-X 100, 150 mM NaCl, 2 mM EDTA. Supple-
mented with protease inhibitor before use). Next, thechromatin was pre-cleared by adding 100 μl agarose A/G
beads (Santa Cruz) at 4 °C for 2 h with constant rotation. The
mixture was centrifuged at 4 °C 2000 rpm for 5 min. The su-
pernatant was removed, retaining 1% as an input. The re-
mainder of the diluted chromatin was then aliquoted into
1.5 ml tubes with an aliquot per ChIP antibody.
(2) To perform the ﬁrst ChIP, 6 μg of antibody (IgG control (Santa
Cruz sc-2027), anti-SUMO1 (Santa Cruz sc-9060), and anti-
MeCP2 (Millipore 07013)) was added to each tube of the di-
luted chromatin and rocked overnight at 4 °C. Following the
overnight incubation, agarose A/G beads (150 μl) were added
to each sample and rotated for an additional 2–4 h at 4 °C.
(3) The beads were pelleted and washed once each with Buffer 1
(0.1% SDS, 1%Triton X-100, 2 mM EDTA, 20 mM Tris–HCl (pH
8.0), 150 mM NaCl), Buffer 2 (0.1%SDS, 1% Triton X-100, 2 mM
EDTA, 20 mM Tris–HCl (pH 8.0), 500 mM NaCl), Buffer 3 (1%
NP40, 1% Deoxycholic acid, 1 mM EDTA, 10 mM Tris–HCl (pH
8.0), 250 mM LiCl), and Buffer 4 (2 mM EDTA, 10 mM Tris–HCl
(pH 8.0)). After the ﬁnal wash, the DNA-protein complexes
were eluted twice with 100 μl 10 mM DTT at 37 °C for 30 min
with gentle shaking twice and combined. The beads were
pelleted, the supernatant was saved, and the wash steps with
Buffers 1–4 (iii) were repeated once as described above. The
supernatants were combined from both steps. One tenth of
the eluate was saved as a template for the primary ChIP for
qPCR analysis. The remaining supernatant was diluted with 20
times ChIP dilution buffer and the secondary ChIP was per-
formed beginning with the addition of the second ChIP anti-
body at the above step (ii).
(4) After the ﬁnal wash, as listed above in step (iii), the DNA was
eluted from the beads with 250 μl Elution Buffer (1 mM EDTA,
10 mM Tris–HCl (pH 7.5), 1% SDS) twice for 30 min at room
temperature with constant rotation. Proteinase K (ﬁnal con-
centration 10 μg/ul) and NaCl (ﬁnal concentration 200 mM)
were added to the eluted chromatin from the primary ChIP,
secondary ChIP, and input. The crosslinks were reversed at
65 °C for 4 h to overnight. The DNA was puriﬁed using phenol/
chloroform extraction. The puriﬁed DNA was resuspended in
60 μl double-distilled H20 (ddH20).
2.4. Seq-ChIP quantitative PCR analysis
PCR reactions were set up in triplicate using the primer sets
shown in Table 1. Each PCR was assembled as described in Table 2
using SYBRs Green PCR Master Mix (Life Technologies). The ana-
lysis was performed using the real-time PCR ABI7500 system
(Applied Biosystem). For data analysis 2–(CtAbCtinput). Ct¼cycle
threshold. Statistical analysis was done using the Student's t-test.
A positive result showed a signiﬁcant enrichment of the MeCP2
protein at genomic regions compared with either IgG or the ne-
gative control regions.3. Results
3.1. Scheme of sequential ChIP to detect SUMOylated MeCP2 in
neurons
MeCP2 is an important regulator in the brain [8]. However, the
precise mechanism of action for MeCP2 is unknown. Although
MeCP2 is subjected to numerous PTMs, it is not known where
along the genome SUMOylated MeCP2 binds. SUMO modiﬁcations
can alter its substrate protein–protein interactions, nuclear-cyto-
plasmic location, ubiquitination status, and transcriptional activity
[7]. Thus, the identiﬁcation of regulatory regions harboring SU-
MOylated MeCP2 is crucial for understanding the role for this PTM
Table 2
Composition of Seq-ChIP reaction.
DNA template 3 ml (of the 60 ml)
(Input or ChIP'ed samples)
10 ml 2PCR Master Mix
2 ml 0.2 mM Forward Primer
2 ml 0.2 mM Reverse Primer
ddH2O variable volume (μl)
20 μl Total volume
Table 1
Sequences of PCR primers.
Gamt Chip Forward: 5′-ACGGCTCAGCCACGGAG-3′
Gamt Chip Reverse: 5′-TTGCACTCAAGTGGGTGGG-3′
Mef2c Chip Forward: 5′-CACTTGAGCACACGCGTACA-3′
Mef2c Chip Reverse: 5′-ACCCACACAGAACCTTCAAAGTC-3′
Oprk1 Chip Forward: 5′-GCACCTTGCTGATCCCAAAC-3′
Oprk1 Chip Reverse: 5′-CCACGTTCCTGATGCTCAATT-3′
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neuronal genomic regions, we established a Sequential-ChIP (Seq-
ChIP) system. The scheme of our method is shown in Fig. 1. The
order of the ﬁrst and second ChIP antibodies can be reversed in
this Seq-ChIP technique, to further validate the presence of SU-
MOylated MeCP2 at regulatory regions.
3.2. MeCP2 and SUMO1 occupy several genomic regions targeted by
MeCP2
First, we checked several known MeCP2 targets for individual
MeCP2 and SUMO1 binding using quantitative ChIP (qChIP).
Mouse hippocampal neurons were subjected to qChIP using anti-
SUMO1, anti-MeCP2, and control IgG antibodies. We then tested
the guanidinoacetate methyltransferase (Gamt), the myocyte en-
hancer factor 2C (Mef2c), and the opioid receptor kappa 1 (Oprk1)
promoters for SUMO1 and MeCP2 occupancy. MeCP2 is an acti-
vator at both the Gamt and Oprk1 genes [14]. In contrast, MeCP2 is
a repressor for neuronal Mef2c expression [14,21]. As shown in
Fig. 2, the Gamt, Mef2c, and Oprk1 promoters demonstrate occu-
pancy for both the SUMO1 and MeCP2 proteins.
3.3. Identiﬁcation of SUMOylated MeCP2 at the Gamt promoter
Next, we used our Seq-ChIP technique to determine the pro-
moters occupied by SUMOylated MeCP2 in HT22 cells. We per-
formed Seq-ChIP using anti-MeCP2 as the ﬁrst ChIP antibody,
followed by anti-SUMO1 as the second ChIP antibody. As shown in
Fig. 3A, only the Gamt promoter is occupied by SUMOylated
MeCP2. The Mef2c and Oprk1 promoters do not show an enrich-
ment of SUMOylated MeCP2. We then used Seq-ChIP with anti-
SUMO1 as the ﬁrst and anti-MeCP2 as the second ChIP antibody. In
agreement with what we observed above, SUMOylated MeCP2 is
detected at the Gamt promoter (Fig. 3B). Taken together, SUMOy-
lated MeCP2 occupancy at the Gamt promoter is veriﬁed using
Seq-ChIP with two different antibody schemes. These data suggest
that SUMOylated MeCP2 is present at speciﬁc genomic regions in
neurons.Fig. 1. Scheme of Sequential-Chromatin immunopreciptation (Seq-ChIP) proce-
dure. Chromatin is prepared from neurons. After chromatin shearing, the ﬁrst ChIP
antibody (α-MeCP2) is immunoprecipitated followed by the addition of the second
ChIP antibody (α-SUMO1). The order of the antibody addition can be reversed. The
crosslinks are reversed and the target genomic regions are isolated and char-4. Discussion
In this study, we developed a Seq-ChIP method to detect in vivo
SUMOylated MeCP2 at neuronal regulatory regions (Fig. 1). We
tested several known MeCP2 gene targets (Gamt, Mef2c, and
Oprk1) in our assay. Gamt encodes the guanidinoacetate N-me-
thyltransferase enzyme, important for creatine production, aacterized using PCR for the presence of the SUMOylated MeCP2.
Fig. 2. SUMO1 and MeCP2 are enriched at the Gamt,Mef2c, and Oprk1 promoters in
mouse neurons. Chromatin was harvested from HT22 cells and quantitative chro-
matin immunoprecipitation (qChIP) was performed with primers ﬂanking the
guanidinoacetate methyltransferase (Gamt), the myocyte enhancer factor 2C (Mef2c),
and the opioid receptor kappa 1 (Oprk1) promoters. The ChIP antibody was α-
SUMO1, α-MeCP2, and the IgG control. Relative enrichment was normalized with
input. Graphs indicate three independent biological replicates. Error bars represent
one standard deviation from the mean.
Fig. 3. Sequential-ChIP reveals the occupancy of SUMOylated MeCP2 at the Gamt
promoter. Chromatin was harvested from HT22 cells and sequential-chromatin
immunoprecipitation (Seq-ChIP) was performed two different ways with primers
ﬂanking the guanidinoacetate methyltransferase (Gamt), the myocyte enhancer factor
2C (Mef2c), and the opioid receptor kappa 1 (Oprk1) promoters. (A) The ﬁrst ChIP
antibody (1) was α-MeCP2 and the second ChIP antibody (2) was either α-SUMO1
or the IgG control. (B) The ﬁrst ChIP antibody (1) was α-SUMO1 and the second
ChIP antibody (2) was either α-MeCP2 or the IgG control. Relative enrichment was
normalized with input. Graphs indicate three independent biological replicates.
Error bars represent one standard deviation from the mean. ND¼not detected; n.
s.¼not signiﬁcant.
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MeCP2 has been shown to activate the Gamt gene [14]. Mutations
in the Gamt gene are associated with severe intellectual disability,
an absence or impaired speech, and epilepsy exemplifying the
need for large amounts of energy in the brain [22]. Indeed, each of
these symptoms are present in RTT patients. MeCP2 has been
shown to repress the Mef2c gene [14,21]. Mef2c is a member of the
myocyte enhancer factor 2 (MEF2) transcription factor family and
is a mediator of epigenetic regulatory mechanisms [23]. Mef2c is
essential for neurodevelopment and function including neuro-
genesis, neuronal migration, and synaptic plasticity [23,24].
Mef2c-related disorders include severe intellectual disability with
an absence of speech, limited mobility, hypotonia, and seizures
[25]. All of these clinical presentations resemble those observed in
RTT patients. MeCP2 activates the Oprk1 in neurons [14]. TheOprk1 gene encodes a κ-Opioid receptors, known to modulate
neurotransmission in brain circuits. Mutations of Oprk1 are im-
plicated in depression and anxiety [26]. Importantly, anxiety be-
haviors have long been observed in RTT patients [27].
Our data reveals that although MeCP2 occupies the Gamt,
Mef2c, and Oprk1 promoters; only SUMOylated MeCP2 binds the
Gamt promoter. These results suggest that SUMOylated MeCP2 is
targeted to certain promoters in a context-dependent manner.
MeCP2 has previously been shown to activate the Gamt promoter.
Our results suggest that SUMOylated MeCP2 at Gamt is an acti-
vation mark for this regulatory region. In summary, the technique
described here can be utilized to detect SUMOylated MeCP2 at
speciﬁc loci. It can be modiﬁed to isolate other also SUMOylated
transcription and chromatin factors.Acknowledgment
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